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Abstract
A number of cyclic and linear peptides containing various combinations of amino acids were
evaluated for their Src kinase inhibitory potency. Among all the peptides, cyclic decapeptide
C[RW]5 containing alternative arginine (R) and tryptophan (W) residues was found to be the most
potent Src kinase inhibitor. C[RW]5 showed higher inhibitory activity (IC50 = 2.8 µM) than
C[KW]5, L(KW)5, C[RW]4, and C[RW]3 with IC50 values of 46.9, 69.1, 21.5, and 25.0 µM,
respectively, as determined in a fluorescence intensity-based assay. Thus, the cyclic nature, the
presence of arginine, ring size, and the number of amino acids in the structure of the peptide were
found to be critical in Src kinase inhibitory potency. The IC50 value of C[RW]5 was found to be
0.8 µM in a radioactive assay using [γ-32P]-ATP and polyE4Y as the substrate. C[RW]5 was a
non-competitive Src kinase inhibitor, showing approximately 4-fold more selectivity towards Src
than Abl.
Protein tyrosine kinases (PTKs) are enzymes that catalyze the transfer of the γ-phosphate
group from ATP to the hydroxyl group in tyrosine residues in proteins. Src family kinases
(SFKs) including Src, Yes, Fyn, Fgr, Hck, Lck, Blk, Lyn, and Frk are non-receptor tyrosine
kinases that play critical roles in several cellular signaling pathways. SFKs contain five
distinct functional domains from the N- to C-terminals, including fatty acid acylation, Src
homology 3 (SH3), Src homology 2 (SH2), kinase (containing ATP and substrate binding
sites), and a C-terminal regulatory domain.1 Src contributes a significant role in cell
proliferation, differentiation, and motility in many normal cell lines.2 Overexpression of Src
kinase is observed in different types of cancer cells.3 Thus, the design of potent Src kinase
inhibitors has become a subject of major interest in drug discovery.4, 5 Most of the attention
has been on designing Src kinase inhibitors through blocking Src-dependent substrate
phosphorylation. The kinase domain inhibitors are designed to inhibit the binding of ATP
(ATP binding site inhibitors)6, 7 or the protein substrate (substrate binding site
inhibitors).8–10
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Peptide-based inhibitors with enhanced specificity can be designed and synthesized to target
conserved regions of PTKs, such as substrate binding site, SH3 domain, and the SH2
domain. The sequence of amino acids in the structure of the peptide can mimic the PTK
substrates that target non-conserved regions of PTKs. Thus, peptides can be designed to be
more selective compared to small molecule inhibitors targeting conserved ATP binding site
of PTKs. Furthermore, the diversity of amino acids in the peptide sequence can be used to
generate diversified structures.
In general, linear peptides adopt highly flexible conformations in a solution that could lead
to weak interactions with the desired target. The optimized linear peptides usually show
PTK inhibitory potency in the micromolar range.11 Moreover, linear peptides have limited
stability and low bioavailability because of proteolytic degradation by natural cellular
protease. Thus, further structural modification is required to enhance the stability, potency,
and selectivity of the linear peptides.
Cyclization strategy has been shown to be effective in developing more potent and stable
peptidic and peptidomimetic agents.12–15 Cyclization of peptides has been commonly used
to reduce the conformational freedom of the peptides. Introducing conformational
constraints in peptides make them more stable towards proteases. In addition, cyclization
often results in higher receptor binding affinity towards specific receptors possibly by
decreasing unfavorable entropic effects.16 For example, G7-18NATE peptide (cyclo-
[CH2COWFEGYDNTFPC]-amide) is a non-phosphorylated tyrosine-containing peptide that
was developed to target specifically the SH2 domain of the growth factor receptor bound
protein 7 (Grb7).17 We have previously reported the synthesis of a number of cyclic
peptides, including analogues of Ac-CIYKYY and GpYEEI as Src kinase inhibitors and Src
SH2 domain binding ligands, respectively. Conformational constrained peptides of
CIYKYY significantly improved the inhibitory potency of the peptides against active Src
kinase when compared with the corresponding linear peptide.18 Conformationally
constrained analogs of GpYEEI also showed significantly higher binding affinity towards
the Src SH2 domain.16
However, a detailed mechanistic study of the role of hydrophobicity, charge, and amino acid
sequence on their Src inhibitory potency of cyclic peptides remained elusive. In continuation
of our efforts to develop new cyclic peptide scaffolds as Src kinase inhibitors,11, 19 herein
we report the design and evaluation of cyclic peptides containing charged and hydrophobic
residues for potential applications as a new class of Src kinase inhibitors. The hydrophobic
residues such as aromatic side chains of phenylalanine and tryptophan were expected to
occupy and/or interact with a large hydrophobic pocket19 in the ATP binding site.
Furthermore, the indole ring of tryptophan could mimic the adenine base of ATP in binding
to the nucleotide binding site.
Seven cyclic octapeptides with various combination of L-amino acids, C[RW]4, C[KF]4,
C[KA]4, C[RFEF]2, C[KE]4, C[RE]4, and C[RF]4 (Figure 1), were synthesized by
employing 9-fluorenylmethyloxycarbonyl (Fmoc)-based chemistry according to our
previously reported procedure.20 The design and selection of the cyclic peptides was based
on the presence of hydrophobic (e.g., W, F, A) and charged residues (e.g., K, R, E).
As a representative example, the synthesis of cyclic [KW]5 is depicted in Scheme 1. The
linear peptide (KWKWKWKWKW) was assembled on the H-Trp(Boc)-2-chlorotrityl
chloride resin. After the final deprotection of the N-terminal Fmoc group by piperidine in
DMF (20% v/v), the side chain-protected peptide was cleaved from trityl resin in the
presence of the cleavage cocktail acetic acid/TFE/DCM(1:2:7 v/v/v,) at room temperature to
yield the side chain-protected linear peptide that was used directly for the cyclization
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reaction. The dried crude linear protected peptide was dissolved in DMF/DCM (5:1 v/v).
HOAt (4 equiv) and DIC (4.5 equiv) were added to the mixture, and the solution was stirred
for 4 h. After the cyclization reaction completed the solvents were removed under reduced
pressure. Freshly prepared cleavage cocktail, reagent R, TFA/thioanisole/EDT/anisole
(90:5:3:2 v/v/v/v) was added to the crude product. The mixture was stirred at room
temperature for 2 h. After precipitation of crude peptide in cold diethyl ether (75 mL, Et2O),
the crude peptide was lyophilized and purified by reversed-phase Hitachi HPLC (L-2455) on
a Phenomenex Prodigy 10 µm ODS reversed-phase column (2.1 cm × 25 cm) using a
gradient system to yield cyclic [KW]5. A similar procedure was employed for the synthesis
of other cyclic peptides by using appropriate resins and protected amino acids.
All L-cyclic peptides were evaluated for their Src kinase inhibitory activity (Table 1). The
effect of peptides on the activity of Src kinase was assessed by Transcreener® ADP2
Fluorescence Intensity (FI) Assay. The results of Src kinase inhibitory activity of cyclic
peptides are shown in Table 1 (entries 1–7). Cyclic octapeptides [KF]4, [KA]4, [RFEF]2, and
[KE]4 exhibited no Src kinase inhibition at the highest concentration 300 µM. C[RF]4,
C[RW]4, and C[RE]4 exhibited modest inhibition of Src kinase with IC4 = 21.5–52.6 µM).
Among these three peptides, C[RW]4 showed the highest inhibition of Src kinase with an
IC50 value of 21.5 µM, suggesting that tryptophan residues contributes in Src kinase
inhibition.
To study the effect of the ring size on the Src kinase inhibitory activity, two other cyclic
peptides namely C[RW]3 and C[RW]5 (Table 1, entries 8 and 9) containing six and ten
alternative arginine and tryptophan residues were synthesized, and their Src kinase
inhibitory activities were compared with C[RW]4. C[RW]3 exhibited slightly lower Src
kinase inhibitory activity (IC50 = 25.0 µM) than C[RW]4. On the other hand, decapeptide
C[RW]5 showed 9-fold higher Src kinase inhibitory activity (IC50 = 2.8 µM) versus
C[RW]4, suggesting that the ring size was a critical factor in enhancing Src kinase inhibition
in C[RW] series.
To investigate the role of the constrained cyclic nature of the peptide, the corresponding
linear (RW)5 (L(RW)5) (Figure 2) was designed and synthesized. C[RW]5 and L(RW)5
(Table 1, entries 9 and 11) share the same number and sequence of amino acids. C[RW]5
and L(RW)5 represent constrained and flexible linear peptides, respectively. L(RW)5
inhibited Src kinase with an IC50 value of 7.1 µM, showing 2.5-fold lower inhibition than
C[RW]5 (IC50 = 2.8 µM). These data suggest that the cyclic nature of the peptide contributes
to improving Src kinase inhibitory activity.
To get a better understanding of the effect of the arginine on the Src kinase inhibitory
activity of C[RW]5 and L(RW)5, two homologues cyclic and linear peptides, C[KW]5 and
L(KW)5 (Figure 2) were synthesized by replacing the arginine with lysine and their Src
kinase inhibitory activities were evaluated. C[KW]5 and L(KW)5 inhibited the Src kinase
activity with IC50 values of 46.9 µM and 69.1 µM (Table 1, entries 11 and 12), respectively,
that are significantly lower than the corresponding C[RW]5 (IC50 = 2.8 µM)) and L(RW)5
(IC50 = 7.1 µM)). These data suggest that the presence of arginine is required for optimal Src
inhibitory activity.
In order to determine the selectivity of C[RW]5 toward Src kinase, the IC50 values of the
peptide were ascertained in two other divergent non-receptor protein tyrosine kinases, Abl
and Csk in a radioactive assay using [ -32P]-ATP and polyE4Y as the substrate. Enzyme
activity and inhibition were characterized using the following methods, adapted from
previous work.14,15,21 Csk and Src activity levels were measured from incubations with
polyE4Y (1 mg/mL). CrkL (0.5 mg/mL) was used as a substrate for Abl. C[RW]5 was
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dissolved in 10% DMSO/90% kinase buffer solution (KB10) and diluted in series as needed.
IC50 measurement assay reactions varied in C[RW]5 concentration. Competition assays
varied ATP concentration while maintaining constant concentrations of inhibitor, enzyme
and substrate. Csk and Abl enzymes were incubated with fixed and excess concentration of
substrate in a series of reactions in the presence of different concentrations of C[RW]5 to
calculate the turnover. The measured activity was plotted versus the concentration of
inhibitor to visualize graphically. The IC50 values of C[RW]5 were found to be 0.8 µM,,
00..88 µM, and 3.1 µM for Src, Csk, and Abl kinases, respectively, in the radioactive assay.
These data suggested that the C[RW]5 is approximately 3.9-fold more selective towards Src
and Csk versus Abl.
To evaluate whether the cyclic peptide was competing with ATP, further kinetic analysis
was conducted. Csk and Src were incubated with a range of concentrations of ATP while
substrate turnover was recorded in the presence or absence of the inhibitor. The plot showed
that C[RW]5 followed a noncompetitive inhibition pattern against ATP for both Csk and Src
(Figures 3). A double-reciprocal plot of the obtained data, followed by linear regression
analysis (r2 ≥ 0.997) revealed that the Kcat/Km declined for both enzymes in the presence of
the peptide. For example, Kcat/Km was 1.91, 1.44, and 1.34 min−1.µM−1 in the presence of 0,
0.5, and 1 µM of the inhibitor, respectively, suggesting that the catlytic efficiency of the
enzyme was reduced in the presence of the peptide. The noncompetitive inhibition pattern
indicated that Src and Csk retained a significant capacity to bind ATP. These data suggest
that C[RW]5 is using other potential sites in the catalytic domain for generating kinase
inhibitory activity possibly by binding to an area of the kinase domain with minimal overlap
with the ATP binding site, such as ATP binding site adjacent domains. More mechanistic
studies are required to determine the mode of inhibition and interaction of positively charged
and hydrophobic amino acids in C[RW]5 with amino acids in the kinase domain.
To evaluate the cellular permeability of these two peptides, a comparative intracellular
uptake experiment was carried out by using synthesized fluorescently labeled C[RW]5 and
C[KW]5 namely F•-C[RW]5 and F•-C[KW]5 and Fluorescence Activated Cell Sorter
(FACS). The labeled compounds were incubated with human ovarian carcinoma (SK-OV-3)
cells for 1 h at 37 °C. The cellular uptake of F•-C[WR]5 was found to be approximately 1.8-
fold higher than that of F•-C[WK]5 (Figure 4). These results suggest that both C[RW]5 and
C[KW]5 that contain similar number of amino acids have efficient cellular permeability, but
the presence of the arginine in C[RW]5 improves the cellular uptake when compared to the
corresponding peptide C[KW]5 containing lysine.
In conclusion, a new class of cyclic peptides containing different combinations of amino
acids was evaluated for Src kinase inhibitory activity. To the best of our knowledge, this is
the first report of cyclic peptides containing hydrophobic and positively charged residues as
Src kinase inhibitors. The combination of tryptophan and arginine showed the highest
potency to inhibit the Src kinase activity compared to other peptides. The cyclic nature, ring
size, and the presence of arginine and tryptophan residues were found to contribute
significantly to the Src inhibitory activity. C[RW]5 with an IC50 value of 2.8 µM exhibited a
significantly higher inhibitory potency compared to C[RW]4, L[RW]5, L(KW)5, and
C[KW]4. C[RW]5 was found to be selective to Src versus Abl kinase. The peptide found to
be a noncompetitive inhibitor to ATP. These data suggest that C[RW]5 can be used as a
scaffold for designing Src kinase inhibitors with further structural modifications.
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Figure 1.
Chemical structures of synthesized cyclic peptides.
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Figure 2.
Chemical structures of L(RW)5 and L(KW)5.
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Figure 3.
Pattern of inhibition of (a) Csk and (b) Src by C[RW]5; Lineweaver-Burk plot of 1/V versus
1/ATP with varying concentration of C[RW]5 shows linear noncompetitive inhibition.
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Figure 4.
Cellular uptake of fluorescently-labeled peptides F′-C[KW]5 and F′-C[RW]5 (5 µM) after 1
h incubation.
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Scheme 1.
Solid-phase synthesis of [KW]5.
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Table 1
Src kinase inhibitory activity of peptides.
Entry Peptide IC50a (µM)
1 Cyclic [KF]4 1567.6
2 Cyclic [KA]4 ≥300
3 Cyclic [RFEF]2 ≥300
4 Cyclic [KE]4 ≥300
5 Cyclic [RE]4 52.6
6 Cyclic [RF]4 31.3
7 Cyclic [RW]4 21.5
8 Cyclic [RW]3 25.0
9 Cyclic [RW]5 2.8
10 Cyclic [KW]5 46.9
11 Linear (RW)5 7.1
12 Linear (KW)5 69.1
13 Staurosporine 0.6
14 PP2 0.5
a
The concentration of the compounds that inhibited the enzyme activity by 50%. All the experiments were carried out in triplicate.
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